Peru

Peru is rapidly emerging as a strategic destination within the Latin American life sciences ecosystem, driven by its unique biological wealth and a modernizing healthcare infrastructure.

The nation is globally recognized for its biotechnology innovation centered on its massive biodiversity, which serves as a premier foundation for natural product research and the development of novel active pharmaceutical ingredients (APIs).

In the pharmaceutical sector, Peru maintains a robust market for generic drugs and biosimilars, supported by a regulatory framework that increasingly prioritizes patient access and safety.

The country’s medical device market is currently fueled by a multi-billion dollar public investment portfolio aimed at hospital infrastructure renewal and the integration of digital health solutions in regional hubs like Lima and Piura.

Healthcare innovation in Peru is also making strides in telemedicine and mobile health (mHealth), closing the gap in specialized care for remote Andean and Amazonian populations.

From an academic research perspective, Peru is a critical site for infectious disease studies and tropical medicine, boasting long-standing collaborations with prestigious global institutions.

The clinical trials landscape is expanding as the country streamlines regulatory timelines to attract more international multicenter studies, particularly in oncology and chronic diseases.

As the government promotes private investment, the Peruvian biopharma and medtech sectors offer high-growth potential for global stakeholders.